CraniUS Therapeutics Achieves Major FDA Success with NeuroPASS Technology

CraniUS Therapeutics: A Leap Forward in Neurotechnology

CraniUS Therapeutics, an innovative neurotechnology firm based in Baltimore, has recently celebrated a significant achievement by securing a second FDA 510(k) clearance in merely six weeks. This comes alongside the granting of a U.S. patent for its revolutionary NeuroPASS™ 3 cranial drug delivery system. This one-two punch not only showcases the company's commitment to advancing neuroplastic surgery but also positions it at the forefront of changes in how neurological disorders may be treated.

On October 7, 2026, the company announced that the FDA had granted clearance for the NeuroPASS 2 configuration of its CraniUS® Plate, a pivotal advancement in cranial reconstruction technologies. Designed specifically to accommodate an implantable intracranial pressure sensor, NeuroPASS 2 enhances capabilities previously laid out with the original NeuroPASS 1 clearance, which was obtained just weeks earlier on July 29, 2026.

According to CraniUS CEO Michael Maglin, achieving two clearances in such a short span is a testament to the execution and ambition of the company. The recent advancements not only fortify the regulatory foundation but set the stage for subsequent iterations and enhancements of their technology. Maglin's vision for the NeuroPASS platform expands beyond mere cranial reconstruction, aiming to pioneer a new era of cranial infrastructure that can facilitate therapeutic access to the brain.

The NeuroPASS 2 configuration maintains the indications for use and core technology of its predicate. The surgeon-requested addition of an opening for an intracranial pressure sensor is especially noteworthy, reflecting the company's responsiveness to emerging clinical needs. The device utilizes patient-specific PEEK (polyether ether ketone) construction, ensuring compatibility and safety in various settings. It’s important to emphasize that, although modular implants and sensors are an essential part of the vision for future capabilities, they are not part of the currently cleared device.

With the granting of U.S. Patent No. 12,752,051, CraniUS has fortified its intellectual property surrounding the integrated drug delivery architecture that forms the crux of the upcoming NeuroPASS 3 program. This patent addresses innovative methodologies for drug delivery methodologies that bypass the blood-brain barrier—a significant hurdle in treating many neurological disorders. The existing delivery methods, which often include subcutaneous reservoirs requiring frequent injections or external catheters, are inadequate for long-term treatments.

The patented NeuroPASS 3 system offers a comprehensive solution, integrating a refillable reservoir within a cranial implant. This system aims to manage therapeutic fluid delivery to specific brain sites effectively, serving as a game-changer in the treatment landscape. The NeuroPASS 3 system is expected to leverage advanced technologies—including MEMS-manufactured flow regulators—to maintain a stable flow rate, minimizing complications or variances in delivery rates.

Dr. Chad Gordon, the company's founder, shares a bold vision for the future of cranial reconstructive surgery. He emphasized the importance of moving beyond traditional definitions of cranial repair, recognizing that the NeuroPASS system can facilitate new methods of drug administration that previously seemed unattainable. By creating a comprehensive interface with the brain, CraniUS aims to tackle serious neurological conditions faced by many patients today.

Despite these significant achievements, the NeuroPASS 3 is still in the investigational phases, with CraniUS committed to completing its non-clinical data package and preparing for preclinical studies. They aim to initiate human trials by the second quarter of 2027, an exciting prospect that beckons the potential for transformative impacts on treatment methodologies.

In summary, CraniUS Therapeutics stands at the forefront of a revolution in neuroplastic surgery. Its innovative NeuroPASS platform, enabled by recent FDA clearances and intellectual property protections, promises to reshape how we approach drug delivery within the cranial space. With ambitions to address debilitating neurological conditions and improve patient outcomes, CraniUS is indeed paving the way for future advancements in the field.